Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02510456 · ClinicalTrials.gov registry record
Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging
A clinical trial, sponsored by Boston Medical Center.
- Completed
- Registry status
- 24
- Enrollment target
NCT02510456 is a clinical trial that has completed, run by Boston Medical Center. The registered enrollment target is 24 participants.
The verdict
NCT02510456 has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This study seeks to enroll women with breast cancer undergoing neoadjuvant chemotherapy to evaluate if Diffuse Optical Spectroscopy Imaging (DOSI) can predict a patient response to chemotherapy treatment. DOSI is a noninvasive imaging method that uses harmless near-infrared light using simple wearable probes held against the skin by transparent dressings to predict tumor metabolic activity. It uses nonionizing radiation, requires no external contrast agent and uses low light exposure to human tissue. DOSI scans can be performed frequently at the bedside in settings such as a doctor's office or infusion center.
Interventions
- DEVICE Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort
- DEVICE Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-01 |
| Est. Completion | 2025-05-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02510456
The ClinicalTrials.gov registry entry for NCT02510456 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort is the first listed.
NCT02510456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02510456 about?
NCT02510456 is a clinical study titled "Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging". This study seeks to enroll women with breast cancer undergoing neoadjuvant chemotherapy to evaluate if Diffuse Optical Spectroscopy Imaging (DOSI) can predict a patient response to chemotherapy treatment. DOSI is a noninvasive imaging method that uses harmless near-infrared light using simple wearab...
What is the current status of trial NCT02510456?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2015-01. Estimated completion is 2025-05-08.
What interventions are being tested in trial NCT02510456?
The interventions under investigation include: Diffuse Optical Spectroscopy Imaging (DOSI) - Neoadjuvant Chemo (NAC) Cohort (DEVICE), Diffuse Optical Spectroscopy Imaging (DOSI) - Non-NAC Cohort (DEVICE).
Who is sponsoring clinical trial NCT02510456?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.